Recombinant antibody of anti-human cardiac troponin I as well as construction method and application thereof

A technology of cardiac troponin and recombinant antibody, which is applied in the field of recombinant antibody against human cardiac troponin I and its construction, and can solve problems such as false positives

CN103694355AActive Publication Date: 2014-04-02FAPON BIOTECH INC +1
1 Cites 25 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2014-04-02

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to a recombinant antibody of an anti-human cardiac troponin I. The recombinant antibody comprises a light chain consisting of a light chain variable region of murine antibodies of the anti-human cardiac troponin I and a light chain constant region of human IgG1 and a heavy chain consisting of a heavy chain variable region of murine antibodies of the anti-human cardiac troponin I and a heavy chain constant region of human IgG1. Compared with the murine antibodies, the recombinant antibody has the advantages that specificity and appetency of a parental antibody for identifying antigens are kept, and nonspecific reaction between the parental antibody and an anti-mouse antibody in human serum is avoided. Therefore, according to the clinical diagnosis application aspect, the recombinant antibody has higher application value compared with the murine antibodies. In addition, the invention also relates to a method for constructing the recombinant antibody of the anti-human cardiac troponin I as well as application of the recombinant antibody.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to the field of antibody engineering, in particular to a recombinant antibody against human cardiac troponin I and its construction method and application. Background technique

[0002] Before the 1980s, the World Health Organization (WHO) has always regarded myocardial enzyme activity as one of the diagnostic criteria for acute myocardial infarction (AMI). In the late 1980s, researchers discovered that the sensitivity and specificity of troponin (Tn) was higher than that of phosphocreatine kinase (CK), phosphocreatine kinase isoenzyme (CK-MB), lactate dehydrogenation enzymes and biomarkers such as aspartate aminotransferase. Cardiac troponin I (cTnI) exists only in the myocardium and is a marker of cardiomyocytes. Its abnormal changes can affect the diastolic and systolic functions of the heart, and can be used to diagnose myocardial necrosis and judge myocardial injury. One of the most specific markers is recognized as...

Examples

Embodiment Construction

[0038] The recombinant antibody against human cardiac troponin I of the present invention and its construction method and application will be further described in detail below in conjunction with the accompanying drawings and specific examples.

[0039] One embodiment of the recombinant antibody against human cardiac troponin I comprises the light chain variable region (L chain V region, V L ) and human IgG1 light chain constant region (L chain C region, C L , such as k chain C region (C k) etc.) composed of light chain and heavy chain variable region (H chain V region, V region of murine antibody against human cardiac troponin I H ) and human IgG1 heavy chain constant region (H chain C region, C H ) constitute the heavy chain.

[0040] Among them, the above-mentioned mouse-derived antibody against human cardiac troponin I is produced by a hybridoma cell with the preservation number CCTCC C2013185, and the hybridoma cell is named CTNI-C4, which was deposited in Wuhan City, ...